At the request of ranking Democrats on the House and Senate health and budget committees, the Congressional Budget Office (CBO) assessed how two hypothetical policy changes – a 10 percent permanent reduction in National Institutes of Health (NIH) funding and a nine-month increase in FDA review times for new drug applications (NDAs) – would affect the development of new drugs…. (Colocho, July 21, 2025) #Biosimilars, #Drug Pricing, #Food and Drug Administration, #Prescription Drugs, #Public Health